ReviewCurrent microbiology2025
Molecular Framework of Multidrug Resistance in Pseudomonas aeruginosa.
Review in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antimicrobial resistance (AMR) in Pseudomonas aeruginosa (PA) represents an escalating public health emergency in India, where factors such as unregulated antibiotic usage, limited infection control, and dense hospital environments have precipitated a dramatic rise in multidrug-resistant (MDR) and extensively drug-resistant (XDR) PA isolates. Recent Indian surveillance data indicate that resistance rates among clinical PA isolates often exceed 70% for key antibiotics, with carbapenem resistance surpassing 60% in intensive care settings and up to 98% for agents such as ceftriaxone in some cohorts. The World Health Organization designates PA as a critical-priority pathogen owing to its intrinsic and acquired resistance to nearly all available antibiotics, dramatically compromising patient outcomes, especially in high-burden regions like India. This review synthesizes the epidemiology of PA resistance in India, elucidating both the clinical prevalence and principal societal drivers-including over-the-counter antibiotic distribution and the prevalence of irrational fixed-dose combinations. A comprehensive analysis is provided of the molecular mechanisms underlying AMR in Indian PA isolates: the high prevalence of metallo-β-lactamases (e.g., blaNDM-1, blaVIM), overexpression of efflux pump systems (such as MexAB-OprM in over 50% of MDR isolates), porin loss (notably OprD in carbapenem-resistant strains), target site mutations, and widespread biofilm formation which affects up to 80% of device-related infections. Understanding these pathways is imperative for optimizing therapeutic regimens, informing antimicrobial stewardship, and directing research toward urgently needed new interventions for PA in India's unique clinical landscape. Additionally this review also talks about the various novel strategies which are currently in the development stages that can prove to be potent against PA in the future.
Indexed as
Identifiers
41428077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.